No apparent effect of naproxen on CSF markers of innate immune activation

We studied 78 participants having a parental or multiple‐sibling history of Alzheimer’s disease (AD) in a two‐year randomized placebo‐controlled trial of naproxen 220 mg b.i.d. for mitigation of early AD pathogenesis. Naproxen was detected in cerebrospinal fluid at concentrations ~100 times lower th...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Pierre‐François, Labonté, Anne, Rosa‐Neto, Pedro, Poirier, Judes, Breitner, John C. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562029/
https://www.ncbi.nlm.nih.gov/pubmed/31211178
http://dx.doi.org/10.1002/acn3.788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562029/
https://www.ncbi.nlm.nih.gov/pubmed/31211178
http://dx.doi.org/10.1002/acn3.788

Ejemplares similares